LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

Search

Rhythm Pharmaceuticals Inc

Open

SectorGezondheidszorg

59.72 6.76

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

55.6

Max

59.82

Belangrijke statistieken

By Trading Economics

Inkomsten

-6.2M

-49M

Verkoop

-9.1M

33M

EPS

-0.81

Winstmarge

-151.352

Werknemers

283

EBITDA

-9.5M

-47M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+44.53% upside

Dividenden

By Dow Jones

Volgende Winsten

5 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-319M

3.8B

Vorige openingsprijs

52.96

Vorige sluitingsprijs

59.72

Nieuwssentiment

By Acuity

24%

76%

60 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 mei 2025, 23:40 UTC

Populaire aandelen

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 mei 2025, 23:33 UTC

Belangrijke Marktbewegers

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 mei 2025, 23:25 UTC

Belangrijke Marktbewegers

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 mei 2025, 23:25 UTC

Winsten

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mei 2025, 22:58 UTC

Winsten

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 mei 2025, 21:35 UTC

Winsten

Cisco Systems Names Patterson as CFO, Patel as President

14 mei 2025, 23:59 UTC

Marktinformatie

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 mei 2025, 23:49 UTC

Marktinformatie

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 mei 2025, 23:48 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 mei 2025, 23:48 UTC

Marktinformatie

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 mei 2025, 23:47 UTC

Marktinformatie

Gold Gains on Possible Technical Recovery -- Market Talk

14 mei 2025, 23:34 UTC

Acquisities, Fusies, Overnames

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 mei 2025, 23:10 UTC

Winsten

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mei 2025, 23:07 UTC

Winsten

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 mei 2025, 23:00 UTC

Top Nieuws

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 mei 2025, 22:43 UTC

Winsten

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 mei 2025, 22:34 UTC

Winsten

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 mei 2025, 22:33 UTC

Winsten

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 mei 2025, 22:30 UTC

Winsten

Xero Did Not Declare a Dividend>XRO.AU

14 mei 2025, 22:30 UTC

Winsten

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 mei 2025, 22:30 UTC

Winsten

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 mei 2025, 22:30 UTC

Winsten

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 mei 2025, 22:28 UTC

Winsten

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 mei 2025, 22:28 UTC

Winsten

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 mei 2025, 22:27 UTC

Winsten

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 mei 2025, 22:27 UTC

Winsten

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 mei 2025, 22:23 UTC

Top Nieuws

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 mei 2025, 22:15 UTC

Winsten

Correction to Cisco Earnings Article -- WSJ

14 mei 2025, 21:48 UTC

Winsten

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 mei 2025, 21:37 UTC

Winsten

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Peer Vergelijking

Prijswijziging

Rhythm Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

44.53% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 82.08 USD  44.53%

Hoogste 94 USD

Laagste 72 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Rhythm Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

12

Buy

0

Hold

0

Sell

Technische score

By Trading Central

60 / 65.58Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

60 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.